In 2019, Pantoea piersonii was initially isolated from the interior surfaces of the International Space Station. This microorganism is a species within the genus Pantoea in the family Erwiniaceae, belonging to the order Enterobacterales. Recent literature has documented four cases of its isolation. Despite initial predictions suggesting the non-pathogenicity of P. piersonii strains, evidence from observed cases indicates potential pathogenicity. According to documented evidence in the literature, this microorganism is capable of causing severe and life-threatening conditions, including sepsis. Traditional tests, as well as automated systems, may fail to provide complete differentiation due to these similarities. While MALDI-TOF MS is a valuable tool for identification in clinical diagnostic microbiology, sequencing may be necessary for precise identification. To determine the antibiotic susceptibility profile, various methods can be utilized, including minimum inhibitory concentration determination, disk diffusion testing (Kirby-Bauer test), genotypic resistance assays (PCR and sequencing), and automated systems. The literature reports a limited number of cases associating P. piersonii with human infection. This study contributes to this body of knowledge by reporting a novel case in which P. piersonii was isolated from a tissue sample for the first time. In this case report, the patient achieved recovery following the administration of appropriate antibiotic treatment based on the diagnosis. It underscores the need for precise identification and understanding of its pathogenicity.

• MeSH
• antibakteriální látky * farmakologie   terapeutické užití   MeSH
• enterobakteriální infekce * mikrobiologie   diagnóza   farmakoterapie   MeSH
• lidé MeSH
• mikrobiální testy citlivosti * MeSH
• Pantoea * izolace a purifikace   genetika   patogenita   MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH

Clear-cell renal cell carcinoma (ccRCC) is a common urological malignancy with an increasing incidence. The development of molecular biomarkers that can predict the response to treatment and guide personalized therapy selection would substantially improve patient outcomes. Dysregulation of non-coding RNA (ncRNA) has been shown to have a role in the pathogenesis of ccRCC. Thus, an increasing number of studies are being carried out with a focus on the identification of ncRNA biomarkers in ccRCC tissue samples and the connection of these markers with patients' prognosis, pathological stage and grade (including metastatic potential), and therapy outcome. RNA sequencing analysis led to the identification of several ncRNA biomarkers that are dysregulated in ccRCC and might have a role in ccRCC development. These ncRNAs have the potential to be prognostic and predictive biomarkers for ccRCC, with prospective applications in personalized treatment selection. Research on ncRNA biomarkers in ccRCC is advancing, but clinical implementation remains preliminary owing to challenges in validation, standardization and reproducibility. Comprehensive studies and integration of ncRNAs into clinical trials are essential to accelerate the clinical use of these biomarkers.

• MeSH
• karcinom z renálních buněk * genetika   diagnóza   MeSH
• lidé MeSH
• nádorové biomarkery * genetika   MeSH
• nádory ledvin * genetika   diagnóza   MeSH
• nekódující RNA * genetika   MeSH
• prognóza MeSH
• regulace genové exprese u nádorů MeSH
• stanovení celkové genové exprese MeSH
• transkriptom * MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH

In this study, lactic acid bacteria (LAB) isolation from fermented foods and molecular identification using magnetic bead technology were performed. And then exopolysaccharide (EPS) production possibility was tested in agar medium, and the positive ones were selected for the next step. The bacteria that could produce higher carbohydrate level were grown in MRS medium fortified with whey and pumpkin waste. In our study, 19 different LAB species were identified from fermented products collected from different places in Hatay (Türkiye) province. In molecular identification, universal primer pairs, p806R/p8FPL, and PEU7/DG74 were used for PCR amplification. After that, PCR products purified using paramagnetic bead technology were sequenced by the Sanger sequencing method. The dominant species, 23.8% of the isolates, were identified as Lactiplantibacillus plantarum. As a technological property of LAB, exopolysaccharide production capability of forty-two LAB isolate was tested in agar medium, and after eleven isolates were selected as positive. Two LAB (Latilactobacillus curvatus SHA2-3B and Loigolactobacillus coryniformis SHA6-3B) had higher EPS production capability when they were grown in MRS broth fortified with pumpkin waste and whey. The highest EPS content (1750 mg/L glucose equivalent) was determined in Loigolactobacillus coryniformis SHA6-3B grown in MRS broth fortified with 10% pumpkin waste. Besides the produced EPS samples were validated with FTIR and SEM methods.

• MeSH
• bakteriální polysacharidy * biosyntéza   metabolismus   MeSH
• Cucurbita mikrobiologie   MeSH
• fermentace MeSH
• fermentované potraviny * mikrobiologie   MeSH
• fylogeneze MeSH
• kultivační média chemie   MeSH
• Lactobacillales * izolace a purifikace   klasifikace   genetika   metabolismus   MeSH
• odpadní produkty * analýza   MeSH
• potravinářská mikrobiologie * MeSH
• RNA ribozomální 16S genetika   MeSH
• syrovátka MeSH
• Publikační typ
• časopisecké články MeSH

Corynebacterium (C.) durum je součástí rezidentní flóry dutiny ústní. Jeho podíl na etiologii infekčních onemocnění je nejednoznačný. S vyšším počtem imunoalterovaných pacientů je nutné s ním počítat jako s potenciálním oportunním patogenem. Nejčastěji je izolováno ze sputa, bronchoalveolární lavážní tekutiny, ale také z krve, zejména u imunosuprimovaných pacientů s pneumonií. V tom případě je nutné bakterii přesně identifikovat a nález správně interpretovat. Dříve velmi využívaný komerční test pro určení korynebakterií (API Coryne, BioMerieux) nelze použít pro všechna korynebakteria včetně C. durum. Tento druh není obsažen v databázi biotypových čísel. Lze provést porovnání biotypového čísla s údaji v literatuře. K přesnému odlišení od jiných korynebakterií je nutná chemotaxonomická a proteomická analýzy (MALDI-TOF MS), nebo sekvenace genu 16S rRNA. Klíčový je polyfázový přístup využívající poznatky z jednotlivých laboratorních vyšetření.

Corynebaterium (C.) durum is a part of the resident human oral microbiota. Its role in the aetiology of infectious diseases is ambiguous. With the increasing number of immunocompromised patients, it must be considered a potential opportunistic pathogen. It is isolated from the sputum, bronchoalveolar-lavage fluid, as well as blood, especially from immunocompromised patients with pneumonia. In that case, the critical steps involve a correct identification of Corynebacterium to the species level and right interpretation of the findings. The previously widely used commercial test for the identification of Corynebacteria (API Coryne, BioMerieux) is not suitable for all species, including C. durum, as its biotype number is not included in the database. But the obtained result can be compared with the available literature data. Chemotaxonomic and proteomic analysis (matrix-assisted laser desorption/ ionization – time of flight, MALDI-TOF MS) or 16S rRNA sequencing allow for accurate differentiation from the other Corynebacteria species. Nevertheless, these methods are not routinely used in clinical laboratories. A polyphasic approach to the taxonomy based on the data from combined laboratory tests is crucial.

BackgroundOn 29 January 2024, the European Centre for Disease Prevention and Control distributed an alert about a metronidazole-resistant Clostridioides difficile outbreak of PCR ribotype (RT) 955 in England.AimWe aimed to investigate the presence of RT955 in Czech, Slovak and Polish C. difficile isolates and evaluate different culture media for detecting its metronidazole resistance.MethodsIsolates with binary toxin genes identified as 'unknown' by the WEBRIBO PCR ribotyping database up to 2023 were re-analysed after adding the RT955 profile to the database. The RT955 isolates were characterised by whole genome sequencing and tested for susceptibility to 15 antimicrobials.ResultsWe did not find RT955 in Czech (n = 6,661, 2012-2023) and Slovak (n = 776, 2015-2023) isolates, but identified 13 RT955 cases (n = 303, 2021-2023) in three hospitals in Poland. By whole genome multilocus sequence typing, 10 isolates clustered into one clonal complex including a sequence of United Kingdom strain ERR12670107, and shared similar antimicrobial resistance genes/mutations. All 13 isolates were resistant to ciprofloxacin/moxifloxacin, erythromycin/clindamycin and ceftazidime. All isolates had a mutation in the nimB gene promoter and in NimB (Tyr130Ser and Leu155Ile). The metronidazole resistance was detected in all isolates using brain-heart-infusion agar supplemented with haemin and Chocolate agar. Results were discrepant with the European Committee on Antimicrobial Susceptibility Testing-recommended Fastidious anaerobe agar and Brucella blood agar.ConclusionThe identification of clonally related haem-dependent metronidazole-resistant C. difficile RT955 in multiple hospitals indicates a need for prospective surveillance to estimate its prevalence in Europe.

• MeSH
• antibakteriální látky * farmakologie   MeSH
• bakteriální léková rezistence * genetika   MeSH
• Clostridioides difficile * genetika   účinky léků   izolace a purifikace   klasifikace   MeSH
• epidemický výskyt choroby MeSH
• klostridiové infekce * epidemiologie   mikrobiologie   farmakoterapie   MeSH
• lidé MeSH
• metronidazol * farmakologie   MeSH
• mikrobiální testy citlivosti MeSH
• multilokusová sekvenční typizace MeSH
• polymerázová řetězová reakce MeSH
• ribotypizace * MeSH
• sekvenování celého genomu MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Česká republika MeSH
• Polsko MeSH
• Slovenská republika MeSH

Proteomics is nowadays increasingly becoming part of the routine clinical practice of diagnostic laboratories, especially due to the advent of advanced mass spectrometry techniques. This review focuses on the application of proteomic analysis in the identification of pathological conditions in a hospital setting, with a particular focus on the analysis of protein biomarkers. In particular, the main purpose of the review is to highlight the challenges associated with the identification of specific disease-causing proteins, given their complex nature and the variety of posttranslational modifications (PTMs) they can undergo. PTMs, such as phosphorylation and glycosylation, play critical roles in protein function but can also lead to diseases if dysregulated. Proteomics plays an important role especially in various medical fields ranging from cardiology, internal medicine to hemato-oncology emphasizing the interdisciplinary nature of this field. Traditional methods such as electrophoretic or immunochemical methods have been mainstay in protein detection; however, these techniques are limited in terms of specificity and sensitivity. Examples include the diagnosis of multiple myeloma and the detection of its specific protein or amyloidosis, which relies heavily on these conventional methods, which sometimes lead to false positives or inadequate disease monitoring. Mass spectrometry in this respect emerges as a superior alternative, providing high sensitivity and specificity in the detection and quantification of specific protein sequences. This technique is particularly beneficial for monitoring minimal residual disease (MRD) in the diagnosis of multiple myeloma where traditional methods fall short. Furthermore mass spectrometry can provide precise typing of amyloid proteins, which is crucial for the appropriate treatment of amyloidosis. This review summarizes the opportunities for proteomic determination using mass spectrometry between 2012 and 2024, highlighting the transformative potential of mass spectrometry in clinical proteomics and encouraging its wider use in diagnostic laboratories.

• MeSH
• amyloidóza * diagnóza   MeSH
• biologické markery analýza   MeSH
• hmotnostní spektrometrie * metody   MeSH
• lidé MeSH
• mnohočetný myelom * diagnóza   MeSH
• posttranslační úpravy proteinů MeSH
• proteomika * metody   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH

Background: Stenotrophomonas infections are becoming more widespread around the world and can be counted as a "newly emerging pathogen of concern". The present study aimed to detect a variety of Stenotrophomonas species (S. maltophilia) using specific 23S rRNA gene primers and investigate their multi-drug resistance potential.Methods: This study includes 375 clinical samples from different clinical sources 175 from males and 200 from females collected from Mosul City Hospital. Identification of Stenotrophomonas was conducted through multiple steps including culturing methods, molecular methods in addition to some biochemical tests 11(3%) of isolates belonged to Stenotrophomonas maltophilia. The isolates understudy were tested for their ability to resist 10 different antibiotics using the Kirby-Bauer disk diffusion method.Results: The resistance rate to amoxicillin, gentamicin, and amikacin (100%), cefixime (91%), imipenem (64%), meropenem(55%), Azithromycin (36%), nalidixic acid and trimethoprim (18%), ciprofloxacin(0%). The virulence factors of S. maltophilia siderophores were found in all (11) isolates belonging to S. maltophilia at a percentage (100%). The result of PCR assay using specific primers designed for detecting 23S rRNA genes of S. maltophilia gives amplification for 11 isolates from 14 suspected isolates. Nucleic acid sequencing for the 23S rRNA gene shows that all isolates belong to S. maltophilia with a similarity rate (91-99) in NCBI.Because the 23S rRNA gene sequence in Stenotrophomonas species shows more variety in this location this study used specific 23S rRNA gene primers to identify S. maltophilia.Conclusion: The study used phenotypic and molecular diagnostic techniques to isolate the bacteria, including the S rRNA23 gene. The results emphasize the need for increased vigilance in hospitals to prevent the spread of antibiotic-resistant bacteria and the development of new treatment strategies.

• MeSH
• antibiotická rezistence genetika   MeSH
• bakteriální léková rezistence genetika   MeSH
• infekce spojené se zdravotní péčí genetika   mikrobiologie   MeSH
• klinická studie jako téma metody   MeSH
• lidé MeSH
• mikrobiologické techniky metody   MeSH
• polymerázová řetězová reakce metody   MeSH
• RNA ribozomální 23S * analýza   genetika   MeSH
• siderofory analýza   genetika   MeSH
• Stenotrophomonas maltophilia * genetika   patogenita   MeSH
• Check Tag
• lidé MeSH

UNLABELLED: The paper presents the study of a set of isolates of Streptococcus pneumoniae, which comprised two heterogeneous subpopulations, one of which was susceptible and the other resistant to optochin. The aim of the study was to compare the results of serotyping, multilocus sequence typing (MLST), ribosomal multilocus sequence typing (rMLST), and variation analysis of these subpopulations and to investigate the genetic probable causes of optochin resistance. The strains studied were cultured from samples taken from patients with invasive pneumococcal disease in the Czech Republic in 2019 and 2020. A total of 10 studied pairs of isolates were subject to serotyping and whole-genome sequencing (WGS). None of the typing methods (serotyping, MLST, or rMLST) applied to pairs of optochin-susceptible and optochin-resistant isolates revealed differences in serotype, sequence type, or ribosomal sequence type. The WGS data analysis identified point mutations in ATP (adenosine triphosphate) synthase genes in 8 of the 10 optochin-resistant isolates. In seven optochin-resistant isolates, the mutation was found in the atpC gene and in one isolate in the atpA gene. One of the mutations in the atpC gene has not yet been published in the literature; it is a mutation at position 143T > C with an amino acid change of Val48Ala. In 8 out of the 10 optochin-resistant isolates, the possible genetic basis for resistance was identified, involving point mutations in the atpA and atpC genes. In the remaining two isolates, no clear genetic explanation for the optochin resistance in S. pneumoniae was found, based on current knowledge. IMPORTANCE: Globally, among the most fundamental tests used for the identification of Streptococcus pneumoniae isolates is determining susceptibility to optochin. In the last 2 decades, optochin-resistant strains have been frequently reported in the literature, which can lead to the misidentification of S. pneumoniae. This study compares whole-genome sequencing data of optochin-susceptible and optochin-resistant subpopulations of S. pneumoniae isolates and investigates the genetic probable causes of resistance in the genomes of optochin-resistant subpopulations.

• MeSH
• antibakteriální látky * farmakologie   MeSH
• bakteriální léková rezistence * genetika   MeSH
• bakteriální proteiny genetika   MeSH
• chinin analogy a deriváty   MeSH
• genom bakteriální MeSH
• lidé MeSH
• mikrobiální testy citlivosti MeSH
• multilokusová sekvenční typizace MeSH
• pneumokokové infekce mikrobiologie   MeSH
• sekvenování celého genomu MeSH
• sérotypizace MeSH
• Streptococcus pneumoniae * genetika   účinky léků   izolace a purifikace   klasifikace   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• srovnávací studie MeSH
• Geografické názvy
• Česká republika MeSH

Genetic diagnosis of rare diseases requires accurate identification and interpretation of genomic variants. Clinical and molecular scientists from 37 expert centers across Europe created the Solve-Rare Diseases Consortium (Solve-RD) resource, encompassing clinical, pedigree and genomic rare-disease data (94.5% exomes, 5.5% genomes), and performed systematic reanalysis for 6,447 individuals (3,592 male, 2,855 female) with previously undiagnosed rare diseases from 6,004 families. We established a collaborative, two-level expert review infrastructure that allowed a genetic diagnosis in 506 (8.4%) families. Of 552 disease-causing variants identified, 464 (84.1%) were single-nucleotide variants or short insertions/deletions. These variants were either located in recently published novel disease genes (n = 67), recently reclassified in ClinVar (n = 187) or reclassified by consensus expert decision within Solve-RD (n = 210). Bespoke bioinformatics analyses identified the remaining 15.9% of causative variants (n = 88). Ad hoc expert review, parallel to the systematic reanalysis, diagnosed 249 (4.1%) additional families for an overall diagnostic yield of 12.6%. The infrastructure and collaborative networks set up by Solve-RD can serve as a blueprint for future further scalable international efforts. The resource is open to the global rare-disease community, allowing phenotype, variant and gene queries, as well as genome-wide discoveries.

• MeSH
• databáze genetické MeSH
• exom genetika   MeSH
• genom lidský genetika   MeSH
• genomika * metody   MeSH
• lidé MeSH
• rodokmen MeSH
• výpočetní biologie metody   MeSH
• vzácné nemoci * genetika   diagnóza   MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Evropa MeSH

• MeSH
• cytogenetika MeSH
• terminologie jako téma MeSH

• Konspekt
• Obecná genetika. Obecná cytogenetika. Evoluce
• NLK Obory
• cytologie, klinická cytologie
• genetika, lékařská genetika
• NLK Publikační typ
• kolektivní monografie